• 267 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    Emerging molecular therapies in the treatment of bladder cancer
    Bladder cancer is a leading cancer type in men. The complexity of treatment in late-stage bladder cancer after systemic spread through the lymphatic system highlights the importance of modulating di [...] Read more.
    Scott D. Bell ... Yujiang Fang
    Published: August 29, 2024 Explor Target Antitumor Ther. 2024;5:1135–1154
    DOI: https://doi.org/10.37349/etat.2024.00267
    This article belongs to the special issue Emerging Molecular Targets and Therapies of Genitourinary Tumors
    View:448
    Download:22
    Times Cited: 0
    Open Access
    Review
    Therapy resistance in prostate cancer: mechanism, signaling and reversal strategies
    Prostate cancer (PC) depicts a major health challenge all over the globe due to its complexities in the treatment and diverse clinical trajectories. Even in the advances in the modern treatment stra [...] Read more.
    Neha Thakur ... Sunny Dholpuria
    Published: August 29, 2024 Explor Target Antitumor Ther. 2024;5:1110–1134
    DOI: https://doi.org/10.37349/etat.2024.00266
    This article belongs to the special issue Mechanisms of Targeted Therapy Resistance and Reversal Strategies
    View:545
    Download:18
    Times Cited: 0
    Open Access
    Original Article
    Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort
    Aim: Human epidermal growth factor receptor-2 (HER2) is a well-established prognostic and predictive biomarker. It is an FDA-approved therapeutic target for HER2 positive breast, gastroesophageal [...] Read more.
    Saurav Verma ... Daniel Breadner
    Published: August 22, 2024 Explor Target Antitumor Ther. 2024;5:1100–1109
    DOI: https://doi.org/10.37349/etat.2024.00265
    View:489
    Download:10
    Times Cited: 0
    Open Access
    Review
    Anticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment
    Cancer remains a concern after years of research in this field. Conventional therapies such as chemotherapy, radiation, and surgery are available for cancer treatment, but they are characterized by  [...] Read more.
    Apurva Sood ... Anuradha Sharma
    Published: August 21, 2024 Explor Target Antitumor Ther. 2024;5:1074–1099
    DOI: https://doi.org/10.37349/etat.2024.00264
    View:503
    Download:23
    Times Cited: 0
    Open Access
    Review
    Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodulation
    Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognostics and substantial therapeutic challenges, with dismal survival rates. Tumor resistance in PDAC is primarily attributed to i [...] Read more.
    Vishali Moond ... Nirav C. Thosani
    Published: August 15, 2024 Explor Target Antitumor Ther. 2024;5:1056–1073
    DOI: https://doi.org/10.37349/etat.2024.00263
    This article belongs to the special issue Molecular Mechanisms and Intervention Options in Metastatic Spread of Cancer
    View:840
    Download:25
    Times Cited: 0
    Open Access
    Review
    Hematopoietic and leukemic stem cells homeostasis: the role of bone marrow niche
    The bone marrow microenvironment (BMM) has highly specialized anatomical characteristics that provide a sanctuary place for hematopoietic stem cells (HSCs) that allow appropriate proliferation, main [...] Read more.
    Shaimaa Khattab ... Pier Paolo Piccaluga
    Published: August 15, 2024 Explor Target Antitumor Ther. 2024;5:1027–1055
    DOI: https://doi.org/10.37349/etat.2024.00262
    This article belongs to the special issue Mechanisms of Targeted Therapy Resistance and Reversal Strategies
    View:471
    Download:14
    Times Cited: 0
    Open Access
    Review
    Prospects for breast cancer immunotherapy using microRNAs and transposable elements as objects
    One of the directions in treatment of chemoresistant breast cancer (BC) may include new methods of activating the immune response against tumor cells. Clinically used checkpoint inhibition using ant [...] Read more.
    Rustam Nailevich Mustafin
    Published: August 06, 2024 Explor Target Antitumor Ther. 2024;5:1011–1026
    DOI: https://doi.org/10.37349/etat.2024.00261
    View:592
    Download:19
    Times Cited: 0
    Open Access
    Review
    Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials
    Tumors with an impaired ability to repair DNA double-strand breaks by homologous recombination, including those with alterations in breast cancer 1 and 2 (BRCA1 and BRCA2) genes, are very sensitive  [...] Read more.
    Martina Panebianco ... Mario Rosario D’Andrea
    Published: August 02, 2024 Explor Target Antitumor Ther. 2024;5:997–1010
    DOI: https://doi.org/10.37349/etat.2024.00260
    This article belongs to the special issue Molecular Mechanisms and Intervention Options in Metastatic Spread of Cancer
    View:416
    Download:19
    Times Cited: 0
    Open Access
    Review
    Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy
    Accurate identification of prostate cancer Gleason grade group remains an important component of the initial management of clinically localized disease. However, Gleason score upgrading (GSU) from b [...] Read more.
    Shayan Smani ... Michael S. Leapman
    Published: July 30, 2024 Explor Target Antitumor Ther. 2024;5:981–996
    DOI: https://doi.org/10.37349/etat.2024.00259
    View:460
    Download:20
    Times Cited: 0
    Open Access
    Commentary
    The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC)
    The landscape of treatment for first-line therapy in advanced urothelial cancer (aUC) and metastatic urothelial cancer (mUC) has rapidly changed in the last year alone. Maintenance avelumab remains  [...] Read more.
    Minira Aslanova ... Jeanny B. Aragon-Ching
    Published: July 29, 2024 Explor Target Antitumor Ther. 2024;5:971–980
    DOI: https://doi.org/10.37349/etat.2024.00258
    This article belongs to the special issue Emerging Molecular Targets and Therapies of Genitourinary Tumors
    View:513
    Download:38
    Times Cited: 0